{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:58:29Z","timestamp":1790639909427,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"DOI":"10.1007\/s00198-026-08241-w","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:59:18Z","timestamp":1790578758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6814-9920","authenticated-orcid":false,"given":"Tomonori","family":"Kobayakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9320-1893","authenticated-orcid":false,"given":"Hiroto","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"8241_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. Jama 285:785\u2013795","journal-title":"Jama"},{"key":"8241_CR2","doi-asserted-by":"crossref","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, the Committees of Scientific A, National Societies of the International Osteoporosis F (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344","DOI":"10.1007\/s00198-018-4704-5"},{"key":"8241_CR3","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S et al (2014) Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 25:2359\u20132381","journal-title":"Osteoporos Int"},{"key":"8241_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5312\/wjo.v7.i3.171","volume":"7","author":"P Pisani","year":"2016","unstructured":"Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E et al (2016) Major osteoporotic fragility fractures: Risk factor updates and societal impact. World J Orthop 7:171\u2013181","journal-title":"World J Orthop"},{"key":"8241_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-25. J Bone Miner Res 22:465\u2013475","journal-title":"J Bone Miner Res"},{"key":"8241_CR6","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R, Ebeling PR, Jan De Beur S, Langdahl B et al (2024) Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res 39:1393\u20131405","journal-title":"J Bone Miner Res"},{"key":"8241_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40520-024-02826-3","volume":"36","author":"N Veronese","year":"2024","unstructured":"Veronese N, Briot K, Gua\u00f1abens N, Albergaria BH, Alokail M, Al-Daghri N et al (2024) Recommendations for the optimal use of bone forming agents in osteoporosis. Aging Clin Exp Res 36:167.","journal-title":"Aging Clin Exp Res"},{"key":"8241_CR8","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","volume":"94","author":"F Cosman","year":"2009","unstructured":"Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV et al (2009) Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 94:3772\u20133780","journal-title":"J Clin Endocrinol Metab"},{"key":"8241_CR9","doi-asserted-by":"publisher","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A et al (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Jt Bone Spine 88:105219","journal-title":"Jt Bone Spine"},{"key":"8241_CR10","doi-asserted-by":"publisher","first-page":"101068","DOI":"10.1016\/j.bonr.2021.101068","volume":"14","author":"T Kobayakawa","year":"2021","unstructured":"Kobayakawa T, Suzuki T, Nakano M, Saito M, Miyazaki A, Takahashi J et al (2021) Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: a prospective cohort study. Bone Rep 14:101068","journal-title":"Bone Rep"},{"key":"8241_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00774-023-01477-0","volume":"42","author":"A Miyauchi","year":"2024","unstructured":"Miyauchi A, Hamaya E, Shimauchi J, Yoshinaga Y, Nishi K (2024) Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study. J Bone Miner Metab 42:77\u201389","journal-title":"J Bone Miner Metab"},{"key":"8241_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E, Bruy\u00e8re O, Veronese N, Lorentzon M et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31:1\u201312","journal-title":"Osteoporos Int"},{"key":"8241_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","volume":"81","author":"MS Ominsky","year":"2015","unstructured":"Ominsky MS, Brown DL, Van G, Cordover D, Pacheco E, Frazier E et al (2015) Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. Bone 81:380\u2013391","journal-title":"Bone"},{"key":"8241_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","volume":"84","author":"S Taylor","year":"2016","unstructured":"Taylor S, Ominsky MS, Hu R, Pacheco E, He YD, Brown DL et al (2016) Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Bone 84:148\u2013159","journal-title":"Bone"},{"key":"8241_CR15","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/jbmr.3439","volume":"33","author":"F Cosman","year":"2018","unstructured":"Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C et al (2018) Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res 33:1407\u20131416","journal-title":"J Bone Miner Res"},{"key":"8241_CR16","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"8241_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141\u2013149","journal-title":"Endocrinology"},{"key":"8241_CR18","doi-asserted-by":"publisher","first-page":"115651","DOI":"10.1016\/j.bone.2020.115651","volume":"142","author":"A Makino","year":"2021","unstructured":"Makino A, Hasegawa T, Takagi H, Takahashi Y, Hase N, Amizuka N (2021) Frequent administration of abaloparatide shows greater gains in bone anabolic window and bone mineral density in mice: a comparison with teriparatide. Bone 142:115651","journal-title":"Bone"},{"key":"8241_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. Jama 316:722\u2013733","journal-title":"Jama"},{"key":"8241_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1109\/TMI.2016.2593346","volume":"36","author":"L Humbert","year":"2017","unstructured":"Humbert L, Martelli Y, Fonolla R, Steghofer M, Di Gregorio S, Malouf J et al (2017) 3D-DXA: assessing the femoral shape, the trabecular macrostructure and the cortex in 3D from DXA images. IEEE Trans Med Imaging 36:27\u201339","journal-title":"IEEE Trans Med Imaging"},{"key":"8241_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2013executive summary. Arch Osteoporos 7:3\u201320","journal-title":"Arch Osteoporos"},{"key":"8241_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Min Res 8:1137\u20131148","journal-title":"J Bone Min Res"},{"key":"8241_CR23","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00198-006-0127-9","volume":"17","author":"JA Shepherd","year":"2006","unstructured":"Shepherd JA, Fan B, Lu Y, Lewiecki EM, Miller P, Genant HK (2006) Comparison of BMD precision for Prodigy and Delphi spine and femur scans. Osteoporos Int 17:1303\u20131308","journal-title":"Osteoporos Int"},{"key":"8241_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jocd.2016.03.003","volume":"19","author":"EM Lewiecki","year":"2016","unstructured":"Lewiecki EM, Binkley N, Morgan SL, Shuhart CR, Camargos BM, Carey JJ et al (2016) Best practices for dual-energy X-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance. J Clin Densitom Off J Int Soc Clin Densitom 19:127\u2013140","journal-title":"J Clin Densitom Off J Int Soc Clin Densitom"},{"key":"8241_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00198-020-05806-1","volume":"32","author":"R Winzenrieth","year":"2021","unstructured":"Winzenrieth R, Ominsky MS, Wang Y, Humbert L, Weiss RJ (2021) Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling. Osteoporos Int 32:575\u2013583","journal-title":"Osteoporos Int"},{"key":"8241_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A et al (2019) Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34:632\u2013642","journal-title":"J Bone Miner Res"},{"key":"8241_CR27","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"8241_CR28","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/0193841X05275596","volume":"29","author":"JK Luellen","year":"2005","unstructured":"Luellen JK, Shadish WR, Clark MH (2005) Propensity scores: an introduction and experimental test. Eval Rev 29:530\u2013558","journal-title":"Eval Rev"},{"key":"8241_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"8241_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"8241_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/jbmr\/zjae028","volume":"39","author":"EM Lewiecki","year":"2024","unstructured":"Lewiecki EM, Betah D, Humbert L, Libanati C, Oates M, Shi Y et al (2024) 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate. J Bone Miner Res 39:473\u2013483","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08241-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08241-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08241-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:02:55Z","timestamp":1790636575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08241-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":31,"alternative-id":["8241"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08241-w","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been performed in accordance with the 1964 Declaration of Helsinki and its later amendments, and approved by the ethical committee of Chutoen General Medical Center (Approval No. 3009251127).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for treatment and clinical data use was obtained from all participants. For the additional retrospective 3D-Shaper analysis, study information was publicly disclosed at the participating institutions, and participants were provided the opportunity to opt out.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest. Tomonori Kobayakawa has received payments for lectures from Amgen, Asahi-Kasei, Daiichi Sankyo, Eli Lilly Japan, and Teijin Pharma Ltd. TN, TK, and FN declare that they have no conflicts of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}